8:20-8:30AM

Welcome and Opening Remarks

9:30-10:30AM

Plenary Panel
Structuring R & D to Maximize Innovation and Productivity: Has Industry Right-Sized its Infrastructure?

R&D innovation, funding, and restructuring are critical issues in navigating pharma’s collective patent cliff.  How have Big Pharma companies combined restructuring and outsourcing initiatives with new discovery and development models to maintain or boost R&D productivity?  Has industry right-sized its infrastructure for a post-cliff world?   How will pharma distribute the costs of new drug innovation?

Frédéric Brunner, CEO, a-connect (moderator)          

Mikael Dolsten, PhD, MD, President, Worldwide Research and Development
Senior Vice President, Pfizer Inc.

Richard Murray, Ph.D., Senior Vice President, Biologics Research & Development, Merck Research Laboratories

Prof. Dr. Andreas Busch, Head of Pharmaceuticals and Animal Health Research and Member of the Board of Management of Bayer Schering Pharma AG

10:45-12:45PM

Dealmaking in the Age of the Biomarker
10:45-12:15PM

With the growing trend toward personalized medicine, there is a great deal of excitement in the pharmaceutical industry around the role of biomarkers in product development and licensing. More companies are incorporating this into their development plans and indicating a greater desire for some form of companion diagnostic when considering assets for licensing.

The commercial implications of incorporating a companion diagnostic can vary significantly depending on the asset and may impact development priorities, costs and timelines. This can also influence differentiation in the market, fit within the treatment paradigm, payer acceptance and, ultimately, adoption and revenue.

This panel will examine the change in the paradigm of this market, look at the share of molecules considering a companion diagnostic component, and discuss what this means for dealmaking as a whole.

Question to be addressed include:

• • How much does the existence of a companion diagnostic influence the valuation of a specific asset?
• • Does this imply the relevance of a business model centered on personalized medicine and diagnostics—and what are the implications for those assets that do not claim potential for a companion diagnostic?
• • Are companion diagnostics the next big licensing trend…or are they overrated?

Moderator: Gautam Aggarwal, Senior Practice Executive, Campbell Alliance

Erle Mast, Executive VP and CFO, Clovis Oncology

Sun Park, VP of Business Development, MedImmune

Premal S. Shah, Ph.D., Director, Business Development, Genomic Health, Inc.

Presented by Campbell Alliance

2:00-3:00PM

3:30-4:30PM

Thinking Beyond Clinical: Create an Optimal Commercial Reimbursement Landscape

Strategic partnering doesn't end with the clinical- coverage, coding and reimbursement have a critical impact now on the partnering decision making process, more than ever.  With constant changes happening in Washington, whether on Capitol Hill or within HHS agencies, consideration of the long term implications of today's coverage and reimbursement policy process is paramount to a well-thought strategic partnering arrangement.  This session will hear presentations from experts in policy, reimbursement and regulatory, as well as hear expert opinion and commentary from the industry as well as public/private payers.

Jeffrey E. Fetterman, President ParagonRx International, LLC (presenter/moderator)

Nathan White, Executive Director, Access & Reimbursement inVentiv Patient Access Solutions (presenter)

Joff Masukawa, VP, Global Government Relations and Public Policy, Shire

Steve Bloom, VP, Business Development, ZIOPHARM Oncology, Inc.

Shefali Shah, MBA, Sr. Director, Managed Markets inVentiv Health

Presented by InVentiv Health

A Cross Industry Look at R & D Models: Lessons Learned for Pharma

Panelists from senior R&D and innovation executives from the consumer, industrials and technology sectors provide best practices that can be applied to the pharmaceutical industry.

• • Balancing internal R&D and external acquisition
• • Funding strategies for high risk discovery
• • Portfolio management in a crowded product field
• • Managing development in a changing regulatory environment

Simon Goodall, Partner, The Boston Consulting Group (moderator)

Carlos Barroso, President, CJB and Associates; Former SVP of R&D, PepsiCo Global Foods

David Croslin, President, Innovate the Future; Former Chief Technologist, Communications Division, HP

Ramesh Rengarajan, Chief Architect, Strategy and Innovation, Angstroms; Former CTO, GE Water

Presented by GLG

Plenary

M & A and Licensing Dealmaking Trends: Creative Deal Structures For 2011 And Beyond
How are the latest trends in M & A and licensing capturing some of the risk sharing and creative dealmaking for the new pharma players?  How are pharma companies maximizing the value of their deals by changing up traditional alliances and M & As?

Richard Smith, Partner, Life Science Practice, Edwards Angell Palmer & Dodge (moderator)

Gary Gabrielsen, VP, Business Development, Astellas US LLC

Milton H. Grannatt, Ph.D., VP & Head, Negotiations, Respiratory & New Growth Opportunities, Global Business Development & Licensing, Novartis Pharmaceuticals Corporation

Rinko Ghosh, Senior Vice President, Chief Business Officer, Nektar Therapeutics

John DeYoung, Vice President, Worldwide Business Development & Innovation - Oncology, Pfizer, Inc.

James J. O’Mara, Vice President, Business Development, Ironwood Pharmaceuticals